PL373728A1 - Polipeptydowe warianty czynnika VII lub VIIa - Google Patents

Polipeptydowe warianty czynnika VII lub VIIa

Info

Publication number
PL373728A1
PL373728A1 PL03373728A PL37372803A PL373728A1 PL 373728 A1 PL373728 A1 PL 373728A1 PL 03373728 A PL03373728 A PL 03373728A PL 37372803 A PL37372803 A PL 37372803A PL 373728 A1 PL373728 A1 PL 373728A1
Authority
PL
Poland
Prior art keywords
polypeptide variants
variants
factor vii
viia polypeptide
viia
Prior art date
Application number
PL03373728A
Other languages
English (en)
Inventor
Jesper Mortensen Haaning
Kim Vilbour Andersen
Anders Hjelholt Pedersen
Original Assignee
Maxygen Holdings Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Maxygen Holdings Ltd. filed Critical Maxygen Holdings Ltd.
Publication of PL373728A1 publication Critical patent/PL373728A1/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6437—Coagulation factor VIIa (3.4.21.21)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21021—Coagulation factor VIIa (3.4.21.21)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Hematology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Dermatology (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
PL03373728A 2002-04-30 2003-04-29 Polipeptydowe warianty czynnika VII lub VIIa PL373728A1 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US37667902P 2002-04-30 2002-04-30

Publications (1)

Publication Number Publication Date
PL373728A1 true PL373728A1 (pl) 2005-09-05

Family

ID=29401388

Family Applications (1)

Application Number Title Priority Date Filing Date
PL03373728A PL373728A1 (pl) 2002-04-30 2003-04-29 Polipeptydowe warianty czynnika VII lub VIIa

Country Status (22)

Country Link
US (6) US7700733B2 (pl)
EP (1) EP1499719B1 (pl)
JP (2) JP2005523723A (pl)
KR (1) KR101121593B1 (pl)
CN (2) CN1665925A (pl)
AT (1) ATE488581T1 (pl)
AU (2) AU2003221469A1 (pl)
BR (1) BR0309576A (pl)
CA (1) CA2483478A1 (pl)
CY (1) CY1111626T1 (pl)
DE (1) DE60334983D1 (pl)
DK (1) DK1499719T3 (pl)
ES (1) ES2355713T3 (pl)
IL (1) IL164764A (pl)
MX (1) MXPA04010781A (pl)
NZ (1) NZ536340A (pl)
PL (1) PL373728A1 (pl)
PT (1) PT1499719E (pl)
RU (1) RU2004134726A (pl)
SI (1) SI1499719T1 (pl)
WO (1) WO2003093465A1 (pl)
ZA (1) ZA200409475B (pl)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7247708B2 (en) 1997-10-23 2007-07-24 Regents Of The University Of Minnesota Modified vitamin K-dependent polypeptides
US6747003B1 (en) 1997-10-23 2004-06-08 Regents Of The University Of Minnesota Modified vitamin K-dependent polypeptides
CA2739933A1 (en) 2000-02-11 2001-08-16 Bayer Healthcare Llc Factor vii or viia-like molecules
US7812132B2 (en) 2000-04-28 2010-10-12 Regents Of The University Of Minnesota Modified vitamin K-dependent polypeptides
US7220837B1 (en) 2000-04-28 2007-05-22 Regents Of The University Of Minnesota Modified vitamin K-dependent polypeptides
US20030211094A1 (en) 2001-06-26 2003-11-13 Nelsestuen Gary L. High molecular weight derivatives of vitamin k-dependent polypeptides
WO2003093465A1 (en) * 2002-04-30 2003-11-13 Maxygen Holdings Ltd. FACTOR VII OR VIIa POLYPEPTIDE VARIANTS
CA2840692A1 (en) * 2002-09-30 2004-04-08 Bayer Healthcare Llc Fvii or fviia variants having increased clotting activity
CA2519873C (en) 2003-03-20 2012-12-18 Maxygen Holdings Ltd. Fvii or fviia variants
RU2373282C2 (ru) 2003-06-19 2009-11-20 Байер Хелткэр Ллк ВАРИАНТЫ ДОМЕНА GLA ФАКТОРА VII ИЛИ VIIa
ES2381110T3 (es) 2003-09-09 2012-05-23 Novo Nordisk Health Care Ag Polipéptidos de factor VII de coagulación
JP4874806B2 (ja) 2003-12-01 2012-02-15 ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト 液体因子ｖｉｉ組成物のウイルス濾過
CN1917861B (zh) 2003-12-19 2012-03-21 诺和诺德医疗保健公司 因子vii多肽的稳定化固体组合物
WO2006018204A1 (en) 2004-08-17 2006-02-23 Zlb Behring Gmbh Modified vitamin k dependent polypeptides
EP1791555B1 (en) * 2004-09-10 2013-03-13 Pharmaorigin ApS Methods for treating local tracheal, bronchial or alveolar bleeding or hemoptysis
EP2360171A1 (en) 2004-12-23 2011-08-24 Novo Nordisk Health Care AG Reduction of the content of protein contaminants in compositions comprising a vitamin K-dependent protein of interest
WO2006114105A2 (en) * 2005-04-26 2006-11-02 Maxygen Holdings Ltd. Use of modified factor vii for treating bleeding
ES2553160T3 (es) 2005-06-17 2015-12-04 Novo Nordisk Health Care Ag Reducción y derivatización selectivas de proteínas Factor VII transformadas por ingeniería que comprenden al menos una cisteína no nativa
WO2007006808A1 (en) 2005-07-13 2007-01-18 Novo Nordisk Health Care Ag Host cell protein knock-out cells for production of therapeutic proteins
JP5894722B2 (ja) 2005-09-01 2016-03-30 ノボ ノルディスク ヘルス ケア アーゲー 第ｖｉｉ因子ポリペプチドの疎水性相互作用クロマトグラフィ精製
JP5690047B2 (ja) 2005-09-14 2015-03-25 ノボ ノルディスク ヘルス ケア アーゲー ヒト凝固第ｖｉｉ因子ポリペプチド
EP2031968B1 (en) * 2006-04-21 2017-11-22 Wake Forest University Health Sciences Structurally modified acellular tissue engineering scaffolds and methods of production
WO2008025856A2 (en) 2006-09-01 2008-03-06 Novo Nordisk Health Care Ag Modified glycoproteins
JP2010513462A (ja) * 2006-12-20 2010-04-30 バイエル・ヘルスケア・エルエルシー 第ＶＩＩおよび第ＶＩＩａ因子組成物
CA2683443A1 (en) 2007-04-13 2008-10-23 Catalyst Biosciences, Inc. Modified factor vii polypeptides and uses thereof
US10092524B2 (en) 2008-06-11 2018-10-09 Edge Therapeutics, Inc. Compositions and their use to treat complications of aneurysmal subarachnoid hemorrhage
JP2011509978A (ja) 2008-01-18 2011-03-31 ノボ ノルディスク ヘルス ケア アーゲー 選択されたＩＣＨ患者亜集団における脳内出血（ＩＣＨ）後の出血拡大、及び／又は浮腫生成の予防又は減弱のための、第ＶＩＩａ因子又は第ＶＩＩａ因子等価物の使用
TWI465247B (zh) 2008-04-11 2014-12-21 Catalyst Biosciences Inc 經修飾的因子ｖｉｉ多肽和其用途
MX2011000847A (es) 2008-08-06 2011-02-25 Novo Nordisk Healthcare Ag Proteinas conjugadas con eficacia prolongada in vivo.
MX2011007736A (es) 2009-01-22 2011-09-06 Novo Nordisk Healthcare Ag Compuestos de hormona del crecimiento estables.
WO2011015649A1 (en) 2009-08-06 2011-02-10 Novo Nordisk Health Care Ag Growth hormones with prolonged in-vivo efficacy
WO2011018515A1 (en) 2009-08-14 2011-02-17 Novo Nordisk Health Care Ag Method of purifying pegylated proteins
CA2771999A1 (en) 2009-08-24 2011-03-10 Amunix Operating Inc. Coagulation factor vii compositions and methods of making and using same
RS59459B1 (sr) 2010-01-22 2019-11-29 Novo Nordisk Healthcare Ag Hormoni rasta sa produženom in-vivo efikasnošću
MX338357B (es) 2010-01-22 2016-04-13 Novo Nordisk Healthcare Ag Compuestos estables de la hormona de crecimiento.
EP2538956A4 (en) * 2010-02-22 2015-04-22 Edge Therapeutics Inc METHODS AND COMPOSITIONS FOR TREATING HEMORRHAGIC BRAIN DISORDERS
RU2606169C2 (ru) 2011-04-05 2017-01-10 Эдж Терапьютикс Система интравентрикулярной доставки лекарственного средства для улучшения исхода после повреждения головного мозга, нарушающего мозговое кровообращение
US9486507B2 (en) 2011-06-10 2016-11-08 Biogen Ma Inc. Pro-coagulant compounds and methods of use thereof
EP2554161A1 (en) 2011-08-02 2013-02-06 LFB Biotechnologies Pharmaceutical composition comprising factor VII encapsulated in micelles
EP2822577B1 (en) 2012-02-15 2019-02-06 Bioverativ Therapeutics Inc. Recombinant factor viii proteins
JP6256882B2 (ja) 2012-02-15 2018-01-10 アムニクス オペレーティング インコーポレイテッド 第ｖｉｉｉ因子組成物、ならびに組成物の作製方法および用途
WO2013177584A2 (en) * 2012-05-25 2013-11-28 The Children's Hospital Of Philadelphia FVIIa VARIANTS EXHIBITING ALTERED INTERACTION WITH ENDOTHELIAL PROTEIN C RECEPTOR (EPCR) AND METHODS OF USE THEREOF FOR MODULATING HEMOSTASIS
BR112015015182B1 (pt) 2012-12-24 2023-12-26 Coagulant Therapeutics Corporation Variante polipeptídica isolada do fator vii, seu método de preparação e seu uso, e composições farmacêuticas e seus usos
TW201442721A (zh) * 2013-01-23 2014-11-16 Daiichi Sankyo Co Ltd 糖鏈修飾心房利尿鈉肽
US11045523B2 (en) 2013-04-05 2021-06-29 Novo Nordisk Healthcare Ag Formulation of growth hormone albumin-binder conjugate
TW202003554A (zh) 2013-08-14 2020-01-16 美商百歐維拉提夫治療公司 因子ｖｉｉｉ－ｘｔｅｎ融合物及其用途
EA201890423A1 (ru) 2015-08-03 2018-07-31 Биовератив Терапьютикс Инк. Слитые белки фактора ix, способы их получения и применения
MX2019006444A (es) 2016-12-02 2019-10-30 Bioverativ Therapeutics Inc Métodos de tratamiento de artropatía hemofílica utilizando factores de coagulación quiméricos.
PL3793588T3 (pl) 2018-05-18 2025-09-01 Bioverativ Therapeutics Inc. Sposoby leczenia hemofilii a
EP3833381B1 (en) 2019-08-15 2022-08-03 Catalyst Biosciences, Inc. Modified factor vii polypeptides for subcutaneous administration

Family Cites Families (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GR860984B (en) 1985-04-17 1986-08-18 Zymogenetics Inc Expression of factor vii and ix activities in mammalian cells
US5180583A (en) 1985-11-26 1993-01-19 Hedner Ulla K E Method for the treatment of bleeding disorders
US5258288A (en) 1986-07-25 1993-11-02 Genzyme Corporation Vector containing DNA encoding mature human protein S
DK323587D0 (da) 1987-06-25 1987-06-25 Novo Industri As Protein
EP0296413A2 (en) 1987-06-12 1988-12-28 Hoechst Japan Limited Hybrid protein C and method for its preparation
US4904584A (en) 1987-12-23 1990-02-27 Genetics Institute, Inc. Site-specific homogeneous modification of polypeptides
US5648254A (en) 1988-01-15 1997-07-15 Zymogenetics, Inc. Co-expression in eukaryotic cells
JPH0246296A (ja) 1988-08-09 1990-02-15 Hoechst Japan Ltd 雑種プロテインｃ及びその製造方法
US5218092A (en) 1988-09-29 1993-06-08 Kyowa Hakko Kogyo Co., Ltd. Modified granulocyte-colony stimulating factor polypeptide with added carbohydrate chains
JP2928287B2 (ja) * 1988-09-29 1999-08-03 協和醗酵工業株式会社 新規ポリペプチド
US5041376A (en) 1988-12-09 1991-08-20 The Board Of Regents Of The University Of Texas System Method for identifying or shielding functional sites or epitopes of proteins that enter the exocytotic pathway of eukaryotic cells, the mutant proteins so produced and genes encoding said mutant proteins
US5047335A (en) 1988-12-21 1991-09-10 The Regents Of The University Of Calif. Process for controlling intracellular glycosylation of proteins
ES2136595T5 (es) 1989-04-19 2004-04-01 Enzon, Inc. Carbonatos activos de oxidos de polialquileno para la modificacion de polipeptidos.
US5093317A (en) 1989-06-05 1992-03-03 Cephalon, Inc. Treating disorders by application of insulin-like growth factor
US5077214A (en) 1989-07-07 1991-12-31 The Texas A&M University System Use of baculovirus early promoters for expression of foreign genes in stably transformed insect cells
US5580560A (en) 1989-11-13 1996-12-03 Novo Nordisk A/S Modified factor VII/VIIa
US5225537A (en) 1989-12-29 1993-07-06 Zymogenetics, Inc. Methods for producing hybrid phospholipid-binding proteins
DE69101634T4 (de) 1990-01-26 1994-12-01 Immuno Ag Rekombinant hergestellte blutfaktoren, verfahren zur exprimierung besagter blutfaktoren sowie in besagtem prozess verwendeter rekombinanter vaccina-virus.
ATE180834T1 (de) 1990-01-29 1999-06-15 Zymogenetics Inc Antikoagulierende proteine
US5583107A (en) 1990-09-04 1996-12-10 Cor Therapeutics, Inc. Agents affecting thrombosis and hemostasis
US5531916A (en) 1990-10-03 1996-07-02 E. I. Du Pont De Nemours And Company Hydrofluorocarbon cleaning compositions
ATE158816T1 (de) 1990-11-26 1997-10-15 Genetics Inst Expression von pace in wirtszellen und verfahren zu dessen verwendung
WO1992015686A1 (en) 1991-02-28 1992-09-17 Zymogenetics, Inc. Modified factor vii
US5833982A (en) 1991-02-28 1998-11-10 Zymogenetics, Inc. Modified factor VII
US5861374A (en) 1991-02-28 1999-01-19 Novo Nordisk A/S Modified Factor VII
US5788965A (en) 1991-02-28 1998-08-04 Novo Nordisk A/S Modified factor VII
US5817788A (en) 1991-02-28 1998-10-06 Zymogenetics, Inc. Modified factor VII
US5504064A (en) 1991-04-10 1996-04-02 Oklahoma Medical Research Foundation Treatment of bleeding with modified tissue factor in combination with an activator of FVII
GB9122048D0 (en) * 1991-10-17 1991-11-27 Interox Chemicals Ltd Compositions and uses thereof
JPH0720127A (ja) 1993-05-07 1995-01-24 Eisai Co Ltd 各種ｐｉｖｋａの測定方法および測定試薬
EP0699075B1 (en) 1993-05-21 2001-12-12 Zymogenetics, Inc. MODIFIED FACTOR VII for inhibiting vascular restenosis and platelet deposition
DE19531637A1 (de) 1995-08-28 1997-03-06 Immuno Ag Pharmazeutische Zusammensetzung zur Behandlung von Blutgerinnungsstörugnen, Verfahren zur Herstellung derselben und deren Verwendung
US5837843A (en) 1996-11-08 1998-11-17 Oklahoma Medical Research Foundation Modified protein C
CA2271232C (en) 1996-11-08 2005-02-22 Oklahoma Medical Research Foundation Modified protein c and methods of use thereof
WO1998032466A1 (en) 1997-01-29 1998-07-30 Polymasc Pharmaceuticals Plc Pegylation process
JP2001511162A (ja) 1997-02-06 2001-08-07 ノボ ノルディスク アクティーゼルスカブ 付加され、そして／又は除去された付着基を有するポリペプチド−ポリマー結合体
US6475725B1 (en) 1997-06-20 2002-11-05 Baxter Aktiengesellschaft Recombinant cell clones having increased stability and methods of making and using the same
AT407255B (de) 1997-06-20 2001-02-26 Immuno Ag Rekombinanter zellklon mit erhöhter stabilität in serum- und proteinfreiem medium und verfahren zur gewinnung des stabilen zellklons
ES2297889T3 (es) 1997-07-14 2008-05-01 Bolder Biotechnology, Inc. Derivados de hormona de crecimiento y proteinas relacionadas.
ES2339196T3 (es) 1997-07-18 2010-05-17 Novo Nordisk Health Care Ag Uso de fviia o fviiai para el tratamiento de disfuncion endotelial y para la inhibicion de angiogenesis, respectivamente.
US6017882A (en) 1997-10-23 2000-01-25 Regents Of The University Of Minnesota Modified vitamin K-dependent polypeptides
US6747003B1 (en) 1997-10-23 2004-06-08 Regents Of The University Of Minnesota Modified vitamin K-dependent polypeptides
US7247708B2 (en) 1997-10-23 2007-07-24 Regents Of The University Of Minnesota Modified vitamin K-dependent polypeptides
US6693075B1 (en) * 1997-10-23 2004-02-17 Regents Of The University Of Minnesota Modified vitamin K-dependent polypeptides
AT408613B (de) 1998-06-17 2002-01-25 Immuno Ag Pharmazeutisches faktor vii-präparat
ES2220114T3 (es) 1998-10-30 2004-12-01 Novozymes A/S Variantes de proteinas poco alergenicas.
ATE365210T1 (de) 1998-10-30 2007-07-15 Novozymes As Glykosylierte proteine mit reduzierter allergenität
ES2315022T3 (es) 1998-11-06 2009-03-16 Novo Nordisk Health Care Ag Metodo para la produccion de fvii.
WO2000054787A1 (en) 1999-03-16 2000-09-21 The Children's Hospital Of Philadelphia Enhanced gamma-carboxylation of recombinant vitamin k-dependent clotting factors
CA2739933A1 (en) 2000-02-11 2001-08-16 Bayer Healthcare Llc Factor vii or viia-like molecules
US7220837B1 (en) 2000-04-28 2007-05-22 Regents Of The University Of Minnesota Modified vitamin K-dependent polypeptides
JP4455802B2 (ja) 2000-05-03 2010-04-21 ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト ヒト第ｖｉｉ凝固因子変異型
US7160540B2 (en) 2000-06-30 2007-01-09 Regents Of The University Of Minnesota Methods for detecting activity of clottings factors
US6423826B1 (en) 2000-06-30 2002-07-23 Regents Of The University Of Minnesota High molecular weight derivatives of vitamin K-dependent polypeptides
US20030211094A1 (en) 2001-06-26 2003-11-13 Nelsestuen Gary L. High molecular weight derivatives of vitamin k-dependent polypeptides
WO2002022776A2 (en) * 2000-09-13 2002-03-21 Novo Nordisk A/S Human coagulation factor vii variants
MXPA03001984A (es) 2000-09-13 2003-08-29 Novo Nordisk Healthcare Ag Variantes de factor vii de coagulacion humano.
BR0114373A (pt) 2000-10-02 2004-02-17 Novo Nordisk As Célula hospedeira eucariótica, métodos para a produção de fvii e de fviia ou de suas variantes, de uma proteìna dependente de vitamina k e de uma célula hospedeira eucariótica produtora de fvii ou de seu análogo, vetor recombinante, fvii e fviia recombinante ou suas variantes, e, proteìna dependente de vitamina k recombinante
WO2002038162A1 (en) 2000-11-09 2002-05-16 The Scripps Research Institute MODIFIED FACTOR VIIa
CZ20032454A3 (en) 2001-03-22 2004-03-17 Novo Nordisk Health Care Ag Coagulation factor vii derivative
CZ2004427A3 (cs) 2001-09-27 2004-08-18 Novoánordiskáhealthácareáag Polypeptidy lidského koagulačního faktoru VII
US7052868B2 (en) * 2001-09-27 2006-05-30 Novo Nordisk Healthcare A/G Human coagulation factor VII polypeptides
JP2005512524A (ja) 2001-11-02 2005-05-12 ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト ヒト凝固第ｖｉｉ因子ポリペプチド
US7024693B2 (en) * 2001-11-13 2006-04-04 Sun Microsystems, Inc. Filter-based attribute value access control
EP1458408B1 (en) 2001-12-21 2009-04-15 Novo Nordisk Health Care AG Liquid composition of factor vii polypeptides
WO2003093465A1 (en) 2002-04-30 2003-11-13 Maxygen Holdings Ltd. FACTOR VII OR VIIa POLYPEPTIDE VARIANTS
CA2840692A1 (en) * 2002-09-30 2004-04-08 Bayer Healthcare Llc Fvii or fviia variants having increased clotting activity
CA2519873C (en) 2003-03-20 2012-12-18 Maxygen Holdings Ltd. Fvii or fviia variants
RU2373282C2 (ru) 2003-06-19 2009-11-20 Байер Хелткэр Ллк ВАРИАНТЫ ДОМЕНА GLA ФАКТОРА VII ИЛИ VIIa
US7185570B2 (en) 2005-01-18 2007-03-06 Chih-Ching Hsieh Spanner with enhancing structure for positioning electronic devices installed therein
US20060252669A1 (en) 2005-05-06 2006-11-09 Marija Heibel Fabric care composition comprising polymer encapsulated fabric or skin beneficiating ingredient

Also Published As

Publication number Publication date
CN1665925A (zh) 2005-09-07
MXPA04010781A (es) 2005-03-07
CN101942019A (zh) 2011-01-12
US9353365B2 (en) 2016-05-31
DE60334983D1 (de) 2010-12-30
ZA200409475B (en) 2005-09-28
US20060270001A1 (en) 2006-11-30
BR0309576A (pt) 2005-02-09
US20060270002A1 (en) 2006-11-30
IL164764A0 (en) 2005-12-18
US20100260741A1 (en) 2010-10-14
KR20040106424A (ko) 2004-12-17
WO2003093465A1 (en) 2003-11-13
JP2005523723A (ja) 2005-08-11
ES2355713T3 (es) 2011-03-30
US20060270000A1 (en) 2006-11-30
NZ536340A (en) 2006-09-29
EP1499719B1 (en) 2010-11-17
ATE488581T1 (de) 2010-12-15
CA2483478A1 (en) 2003-11-13
US7700733B2 (en) 2010-04-20
PT1499719E (pt) 2011-02-09
SI1499719T1 (sl) 2011-03-31
IL164764A (en) 2013-07-31
DK1499719T3 (da) 2011-02-28
JP2010213706A (ja) 2010-09-30
US20060276377A1 (en) 2006-12-07
RU2004134726A (ru) 2005-06-10
KR101121593B1 (ko) 2012-04-12
CY1111626T1 (el) 2015-10-07
AU2008261165A1 (en) 2009-01-15
US20060111282A1 (en) 2006-05-25
EP1499719A1 (en) 2005-01-26
AU2003221469A1 (en) 2003-11-17

Similar Documents

Publication Publication Date Title
IL164764A0 (en) Factor vii or viia pohypeptide variants
IL199497A0 (en) Polypeptide conjugate comprising human factor vii or human factor viia like molecules, nucleotide sequence encoding therefor, method for production thereof, and uses thereof
EP1644504B8 (en) Factor vii or viia gla domain variants
EP2085096A3 (en) Novel composition and methods for the treatment of immune related diseases
JO2373B1 (en) W-carboxy-aryl diphenyl urease substitutes used as RAV inhibitors
ATE437221T1 (de) Lentivirale vektoren kodierend für gerinnungsfaktoren für die gentherapie
ITMI20010562A1 (it) Inibitori o antagonisti della proteina hmg1 per il trattamento di disordini vascolari
PL350627A1 (en) Medicament for treating diabetes
AP2000001929A0 (en) Substituted indolealkanoic acids.
AU2002351593A1 (en) Pharmaceutical compositions comprising unacylated ghrelin and therapeutical uses thereof
WO2003037932A3 (en) Human coagulation factor vii polypeptides
WO2002032461A3 (en) Protein c or activated protein c-like molecules
IL140917A0 (en) Human anti-factor ix/ixa antibodies
GB9924957D0 (en) Novel treatment
AP2001002377A0 (en) Substituted phenoxyacetic acids.
WO2006028561A3 (en) Novel purified fabi polypeptides from fransicella tularensis
DE60222669D1 (de) Asthma-assoziiertes gen
CA2333252A1 (en) Use of bromelain proteases for inhibiting blood coagulation
FR2830865B1 (fr) Leurres peptidiques pour la preparation de medicaments destines a la prevention ou au traitement des pathologies auto-immunes, ou des troubles lies a l'apparition d'anticorps diriges contre des proteines exogenes
WO2004058811A3 (en) Crystal structures of yhhf polypeptides
IN2009CN00831A (pl)
WO2003055904A3 (en) Peptidyl-trna hydrolase from pseudomonas aeruginosa

Legal Events

Date Code Title Description
DISC Decisions on discontinuance of the proceedings (taken after the publication of the particulars of the applications)
VDSO Invalidation of derivated patent or utility model

Ref document number: 396241

Country of ref document: PL

Kind code of ref document: A1